Latest news about Corona Remedies
Corona Remedies
1,728.30
+45.10(+2.68%)
Company Performance:
View Company Insights1D+2.68%
1M-1.57%
6M+20.15%
1Y+20.15%
5Y+20.15%
More news about Corona Remedies
26May 26
CORONA Remedies promoter declares no encumbrance on shares
Ankur Mehta, Joint Managing Director and Promoter of CORONA Remedies, declared that no encumbrance was made on equity shares held by him or Persons Acting in Concert during FY26. The disclosure, filed under Regulation 31(4) of SEBI SAST Regulations, was submitted to BSE and NSE.
22May 26
CORONA Remedies declares ₹10 dividend for FY26
CORONA Remedies has recommended a final dividend of ₹10 per equity share for FY26, subject to AGM approval, with a record date of June 19, 2026. The company detailed TDS regulations under the Income Tax Act, 2025, specifying rates for residents and non-residents. Shareholders must submit necessary documents like Form 121 and Tax Residency Certificates by June 19, 2026, to avail of beneficial tax rates.
19May 26
Corona Remedies to Participate in Analyst/Investor Conferences on May 26-27, 2026
Corona Remedies Limited has intimated stock exchanges of its participation in two investor conferences in Mumbai on May 26 and May 27, 2026. The first event, Ambit India Access – Titans of Tomorrow, is hosted by Ambit Capital, while the second, TRINITY INDIA 2026, is hosted by 360 ONE Capital (B&K). Both conferences will be attended in-person and will involve Group and 1x1 meetings, with discussions restricted to publicly available information and no unpublished price sensitive information to be shared.
14May 26
CORONA Remedies FY26 PAT Rises 33.4%; Dividend ₹10 Declared
CORONA Remedies Limited announced its audited financial results for the year ended March 31, 2026, reporting a 17.3% increase in standalone revenue to ₹1,403.18 Crores. On a consolidated basis, adjusted PAT rose 33.4% to ₹199.4 Crores, excluding a one-time statutory impact of ₹19.1 Crores from new Labour Codes. The Board recommended a final dividend of ₹10 per share and appointed M/s. Walker Chandio & Co LLP as the Statutory Auditor for five years.
08Apr 26
Corona Remedies Limited Files Quarterly Regulatory Certificate for Q4 FY26
Corona Remedies Limited submitted its quarterly regulatory certificate for Q4 FY26 ended March 31, 2026, to BSE and NSE on April 07, 2026. The certificate, issued by registrar Bigshare Services Private Limited, confirms that SEBI Regulation 74(5) is not applicable as all shares remain in demat form with no rematerialisation or dematerialisation requests during the quarter. This filing represents routine compliance with SEBI depositories regulations for the pharmaceutical company.
07Apr 26
Corona Remedies Reports 87% OCF to EBITDA Ratio, Eyes Further Acquisitions
Corona Remedies has announced an operating cash flow to EBITDA ratio of around 87%, demonstrating strong cash generation capabilities. The company stated that this robust financial position provides adequate room for pursuing further acquisitions as part of its growth strategy, indicating strong operational efficiency and financial flexibility for strategic expansion.
07Apr 26
Corona Remedies Reports ₹112 Crore Cash Reserves, Sets 20-25% Growth Target for Wpladone
Corona Remedies announced cash reserves of ₹112 crore as of December 31 and set a growth target of 20-25% CAGR for its Wpladone product over the next three years. The strong cash position provides financial stability to support the company's ambitious growth strategy.
31Mar 26
CORONA Remedies Limited Acquires Wokadine® Brand from Dr. Reddy's Laboratories in Strategic Deal
CORONA Remedies Limited announced the strategic acquisition of Wokadine® from Dr. Reddy's Laboratories, effective March 30, 2026. This fifth acquisition enables entry into the INR 648 Cr Povidone Iodine market, where Wokadine® holds the #2 position. The brand comprises 14 SKUs and will be integrated into CORONA's existing portfolio to enhance market penetration across multiple medical specialties.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,807.70
(+0.75%)
6,638.00
(-0.26%)
4,571.20
(-0.02%)
1,389.40
(+0.44%)
1,104.70
(-0.11%)
1,275.40
(-0.05%)
2,293.30
(+0.88%)
2,381.10
(+0.35%)
1,472.80
(+0.59%)
1,394.30
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
